Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 10:00:04 pm
46.01 USD   -2.75%
2014Amid Alibaba fever, reasons for caution in IPO market
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Number of employees : 520 people.
Sales per Businesses
20162017Delta
USD (in Million)%USD (in Million)%
Rare Diseases Treatment Products0.133100%---
Collaboration and License--2.1481.8%-
Product--0.47618.2%-
Sales per Regions
20162017Delta
USD (in Million)%USD (in Million)%
United States0.133100%2.61100% +1863.91%
Managers
NameAgeSinceTitle
Emil D. Kakkis MD, PhD572010President, Chief Executive Officer & Director
Daniel G. Welch, MBA602015Non-Executive Chairman
Wladimir Hogenhuis-2018Chief Operating Officer
Shalini Sharp, MBA432012Chief Financial Officer & Executive Vice President
Dennis Karl Huang532015Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian, MD652018Chief Medical Officer & Executive Vice President
Eric Crombez, MD-2017Chief Medical Officer
Samuel C. Wadsworth, PhD--Chief Scientific Officer-Ultragenyx Gene Therapy
William E. Aliski702011Independent Director
Matthew K. Fust, MBA532014Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 50,579,619 47,314,969 93.5% 0 0.0% 93.5%
Shareholders
NameEquities%
Capital Research & Management Co. (Global Investors) 5,856,138 11.6%
Wellington Management Co. LLP 5,274,908 10.4%
Capital Research & Management Co. (International Investors) 4,359,891 8.62%
The Vanguard Group, Inc. 3,951,864 7.81%
BlackRock Fund Advisors 3,546,199 7.01%
Fidelity Management & Research Co. 3,310,512 6.55%
Emil D. Kakkis MD, PhD 3,010,213 5.95%
T. Rowe Price Associates, Inc. 2,778,029 5.49%
SSgA Funds Management, Inc. 1,712,524 3.39%
Capital Research & Management Co. (World Investors) 1,461,390 2.89%
Company contact information
Ultragenyx Pharmaceutical, Inc.
60 Leveroni Court
Novato, CA 94949

Phone : +1.415.483.8800
Fax : +1.415.483.8810
Web : http://www.ultragenyx.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC-0.80%2 327
GILEAD SCIENCES-8.47%84 823
VERTEX PHARMACEUTICALS15.72%43 460
REGENERON PHARMACEUTICALS1.39%40 527
GENMAB3.84%9 952
SAREPTA THERAPEUTICS INC114.81%7 987
NEUROCRINE BIOSCIENCES, INC.-8.06%6 469
EXELIXIS, INC.-30.82%6 288
BLUEBIRD BIO INC-41.95%5 655
BIOCON LTD20.22%5 406
PEPTIDREAM INC19.47%5 115
HUALAN BIOLOGICAL ENGINEERING INC--.--%4 613
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.-35.34%4 360
LOXO ONCOLOGY INC64.97%4 251
TESARO INC-11.08%4 056
SANBIO CO LTD168.39%3 872
ARGEN-X70.60%3 640
ARRAY BIOPHARMA INC24.77%3 403
NOVOCURE LTD76.53%3 317
INTERCEPT PHARMACEUTICALS INC84.89%3 203
AGIOS PHARMACEUTICALS INC-9.87%2 998
Connections : Ultragenyx Pharmaceutical